Contineum Therapeutics has concluded the targeted enrolment of 168 subjects in its Phase II trial of M1 receptor antagonist ...

PTD802 is a selective inhibitor of the GPR17 receptor and is made to restore myelin, a process known as remyelination, in ...

While there’s no cure for multiple sclerosis (MS), there are many treatments ... According to one research review, mesenchymal stem cell (MSC) therapy may help reduce or prevent central nervous ...

Developed under an exclusive worldwide licence agreement with UCB, PTD802 is designed to counteract the effects of ...

spoke to the impacts of processes such as prior authorization and step therapy requirements in the realm of multiple sclerosis (MS). Ocrelizumab and hyaluronidase is now the first and only twice ...

This appears to slow or stop disease progression. For now, stem cell therapy is most likely to help people who have active inflammation or frequent relapses. Research does not suggest it can ...

Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...

The researchers found that a biomarker in the blood called neurofilament light chain (NfL) increased after menopause. This ...

A new study revealed safe MS treatment options during pregnancy, reassuring women to balance effective care with their plans ...

Carried into the hospital on his father’s back, the patient, a 24-year-old engineering student, walked out on his feet after ...

Explore the role of preclinical MRI in studying neurological diseases, with a focus on advanced cellular and molecular ...